The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy

IF 3.8 2区医学 Q2 ONCOLOGY

Current Treatment Options in Oncology Pub Date : 2024-09-11 DOI:10.1007/s11864-024-01246-9

Heng Dong, Zhengguo Zhang, Mengjie Ni, Xiaoyun Xu, Yifeng Luo, Yaru Wang, Haiyun Zhang, Jianxiang Chen

{"title":"The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy","authors":"Heng Dong, Zhengguo Zhang, Mengjie Ni, Xiaoyun Xu, Yifeng Luo, Yaru Wang, Haiyun Zhang, Jianxiang Chen","doi":"10.1007/s11864-024-01246-9","DOIUrl":null,"url":null,"abstract":"<p>Hepatocellular carcinoma (HCC) is a common type of tumor worldwide. The development of systemic treatment of advanced HCC has remained stagnant for a considerable period. During the last years, a series of new treatment regimens based on the combination of immunotherapeutic drugs and targeted drugs have been gradually developed, increased the objective response rate (ORR), overall survival (OS), and progression free survival (PFS) of HCC patients. Among the different combination therapy groups, atezolizumab plus bevacizumab and sintilimab plus IBI-305 seem to have unique advantages, while head-to-head comparisons are still needed. A comprehensive understanding of the developments, the ongoing clinical trials and the mechanisms of combination of immunotherapy and targeted therapy might lead to the development of new combination strategies and solving current challenges such as the molecular biomarkers, the clinical administration order of drugs and the second-line treatments after combination therapy.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"182 1","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-024-01246-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Hepatocellular carcinoma (HCC) is a common type of tumor worldwide. The development of systemic treatment of advanced HCC has remained stagnant for a considerable period. During the last years, a series of new treatment regimens based on the combination of immunotherapeutic drugs and targeted drugs have been gradually developed, increased the objective response rate (ORR), overall survival (OS), and progression free survival (PFS) of HCC patients. Among the different combination therapy groups, atezolizumab plus bevacizumab and sintilimab plus IBI-305 seem to have unique advantages, while head-to-head comparisons are still needed. A comprehensive understanding of the developments, the ongoing clinical trials and the mechanisms of combination of immunotherapy and targeted therapy might lead to the development of new combination strategies and solving current challenges such as the molecular biomarkers, the clinical administration order of drugs and the second-line treatments after combination therapy.

Abstract Image

查看原文本刊更多论文

晚期肝细胞癌的治疗趋势：免疫疗法与靶向疗法相结合

肝细胞癌（HCC）是全球常见的肿瘤类型。在相当长的一段时期内，晚期肝细胞癌的系统治疗一直停滞不前。近年来，一系列基于免疫治疗药物和靶向药物联合治疗的新方案逐渐开发出来，提高了 HCC 患者的客观反应率（ORR）、总生存期（OS）和无进展生存期（PFS）。在不同的联合治疗组中，阿特珠单抗联合贝伐单抗和辛替利单抗联合IBI-305似乎具有独特的优势，但仍需进行头对头比较。全面了解免疫疗法和靶向疗法的发展、正在进行的临床试验以及联合治疗的机制，可能有助于开发新的联合治疗策略，并解决目前面临的挑战，如分子生物标志物、临床用药顺序以及联合治疗后的二线治疗等。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.